Almenoff June Sherie's Form 4 filing
Avalo Therapeutics, Inc. (AVTX) · filed Nov 14, 2024
- Accession no.
- 0001578563-24-000441
- Filed
- Nov 14, 2024
- Trade date
- Nov 12-13, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $12.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Almenoff June SherieCIK 0001492647 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 12, 2024 | Common Stock | PPurchaseAcquired | +500 | $12.50F1 | +$6,250 | 500 | Indirect | |
| Nov 13, 2024 | Common Stock | PPurchaseAcquired | +500 | $13.00 | +$6,500 | 1,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This transaction was executed in multiple trades ranging from $12.00 to $12.50. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.